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BLETTER TO THE EDITOR
aploidentical Stem Cell Transplantation with
urified CD34 Cells after a Chemotherapy-Alone
onditioning Regimen in Heavily Transfused Severe
plastic Anemia
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vAllogeneic stem cell transplantation (SCT) remains
he major curative treatment for patients with severe
plastic anemia (SAA).[1] Although the ideal donor is an
LA genotypically matched sibling, a signiﬁcant num-
er of patients do not have an acceptable donor in the
amily or in the international registries. Therefore, the
ecessity of using alternative donors, such as genotypi-
ally haploidentical family members, is compelling for
oung adults with SAA who lack a suitable HLA-
atched donor. Nonetheless, haploidentical related
CT has rarely been performed in this context, probably
ecause of the high risk of graft failure, which not only is
etermined by the extensive T-cell depletion of the
raft, but also is due to the signiﬁcant exposure of the
atient to transfusion donors. In the literature, there are
few patients with refractory SAA, mostly children, who
ave undergone haploidentical SCT.[2-5] However, the
onditioning regimens almost invariably contained irra-
iation, and, in some cases, T-cell depletion was not
erformed.
Recently, we have published a series of 14 patients
ith high-risk acute leukemia who were successfully
ubmitted to T cell–depleted CD34-selected hap-
oidentical SCT after a chemotherapy-alone condi-
ioning regimen.[6] In this report, we describe the
linical case of an adult patient with heavily transfused
efractory SAA who was successfully treated with hap-
oidentical SCT by using the same chemotherapy-
lone conditioning regimen.
A 26-year-old man presented in September 2002
ith SAA. Because he did not have a suitable HLA-
atched donor, he received 2 courses of antithymocyte
lobulin, cyclosporin A, steroids, and growth factors,
ith no response (Figure 1). He had prolonged admis-
ions with serious infectious complications, including
eptic shock. In November 2003, because of the contin-
ous need for weekly transfusions, the patient was sub-
itted to a haploidentical SCT from his 3/6 HLA-
atched father. There was no natural killer celleactivity of donor versus recipient, evaluated by differ- c
B & M Tnces in HLA typing at the level of HLA-C, -Bw4 and
A3/A11 allotypes, as proposed by Ruggeri et al.[7]
The conditioning regimen consisted of thiotepa 5
g/kg/d on days 9 and 8, ﬂudarabine 40 mg/m2/d
n days 9 to 5, rabbit antithymocyte globulin (Thy-
oglobulin; IMTIX Pasteur Mérieux Connaught, Paris,
rance) 5 mg/kg/d on days7 to3 as a 12- to 24-hour
nfusion, melphalan 60 mg/m2/d on days 4 and 3,
yclosporin 3 mg/kg/d on days 10 to 2, and pred-
isolone 2 mg/kg/d on days 7 to 3, as described
reviously.[6] The father’s peripheral blood stem cells,
ollected on 2 consecutive days, were individually sub-
itted to CD34 cell selection with the automated
liniMacs device (Miltenyi Biotec, Bergisch-Gladbach,
ermany), analyzed by ﬂow cytometry, and cryopre-
erved. On the day of the transplantation, the cells were
hawed and infused without further analysis. The patient
eceived a total of 5.0  106 CD34 cells per kilogram,
.7  103 CD3 cells per kilogram, and 8.3  104
D19 cells per kilogram, and T-cell depletion was the
nly prophylaxis for graft-versus-host disease.
The patient had prompt engraftment, and the day
f neutrophils 500/L and 1000/L was day 13 and
ay 15, respectively. The median day of platelets
20 000/L was day 34. The highest platelet count
ttained after transplantation was 44 000/L on day
8. Chimerism analysis by DNA polymerase chain
eaction performed on day 30 was consistent with
00% donor hematopoiesis. In February 2004, 3
onths after transplantation, the patient presented
ith a progressive decline in peripheral blood counts,
gain necessitating growth factor administration and
eekly transfusions. Although the bone marrow ex-
minations revealed marked hypocellularity, chimer-
sm analysis always showed 100% donor hematopoie-
is. In September 2004, the donor was restimulated,
nd the patient received 1 infusion of CliniMacs
D34-selected T cell–depleted peripheral blood stem
ells, without any conditioning regimen or graft-
ersus-host disease prophylaxis. At this time, he re-
eived 3.66  106 CD34 cells per kilogram, 6  103
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4D3 cells per kilogram, and 3  104 CD19 cells
er kilogram. Since then, he has not received growth
actors or transfusions. Over the following months, we
bserved a recovery of his peripheral blood counts,
nd in February 2005, he is normally active and has a
emoglobin of 13.8 g/dL, a white blood cell count of
270/L, and a platelet count of 144 000/L (Figure
). His bone marrow cellularity is normal, and chi-
erism analysis continues to show 100% donor he-
atopoiesis. Five months after the stem cell boost, he
as 440 106/L CD19, 443 106/L CD56, 172
06/L CD3, 110  106/L CD4, and 226  106/L
D8 cells in the peripheral blood, with no
D4CD45RA cells detected.
This is, to our knowledge, the ﬁrst report of a hap-
oidentical, 3/6 HLA-matched, CD34-selected, exten-
ively T-cell depleted SCT in an adult with heavily
ransfused SAA after a chemotherapy-alone conditioning
egimen. Because the total dose of melphalan was 120
g/m2, it is possible that our regimen is not myeloab-
ative. Nevertheless, it is very immunosuppressive and
as effective in a heavily immunized patient at high risk
or graft failure. In fact, before the transplantation, the
atient received 25 units of red blood cells and 148 units
f platelets, and between the transplantation and the
tem cell boost he received 12 units of red blood cells and
21 units of platelets. The posttransplantation period of
evere pancytopenia, always with 100% donor hemato-
oiesis, suggests that the number of CD34 cells infused
as suboptimal. Our patient received a total CD34 cell
ose of 8.66  106/kg, which is still overestimated be-
ause it does not account for the CD34 cell loss during
he cryopreservation and thawing procedures at the time
f transplantation (the CD34 cell boost was adminis-
ered fresh). With the CD34 cell selection, a 4.5 log10
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igure 1. Platelet count since diagnosis. The stem cell transplan-
ation (SCT) was in November 2003, and the boost was at the end
f September 2004.-cell depletion was obtained in both products. Even L
00hough there is limited information, patients with
eavily transfused SAA should, if possible, receive a
igher CD34 cell dose to ensure consistent engraftment.
Our report suggests that haploidentical related
D34-selected T cell–depleted SCT seems to be a
romising therapeutic approach in adults with heavily
ransfused SAA lacking a suitable HLA-matched do-
or in the family or in the international registries.
owever, further studies and more patients are
eeded before ﬁrm conclusions can be drawn.
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